Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd

Link copied
Case Copied 83 min read

FEDERAL COURT OF AUSTRALIA

Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd [2020] FCAFC 116

Appeal from: Mylan Health Pty Ltd (formerly BGP Products Pty Ltd) v Sun Pharma ANZ Pty Ltd (formerly Ranbaxy Australia Pty Ltd) [2019] FCA 28
File number: NSD 182 of 2019
Judges: MIDDLETON, JAGOT, YATES, BEACH AND MOSHINSKY JJ
Date of judgment: 3 July 2020
Catchwords:

PATENTS – infringement – Swiss type claims – whether mental element imported into claims – whether it is necessary to establish manufacturer’s intention to prove infringement – discussion of correct approach to determining infringement

PATENTS – validity – lack of novelty – prior publication of documents – correct test for determining lack of novelty – whether there can be anticipatory disclosure by prior publication of the invention based on a reasoned hypothesis

PATENTS – validity – lack of inventive step – where case presented on basis of common general knowledge and documentary disclosure – whether primary judge erred in finding lack of inventive step on basis of common general knowledge alone

PATENTS – validity – whether claims fairly based on the matter described in the specification – proper construction of the specification  

Legislation:

Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)

Patents Act 1990 (Cth) ss 7(1)(a), 7(1)(b), 7(2), 7(3), 13(1), 40(3), 117(1), 117(2)(b)

Therapeutic Goods Act 1989 (Cth) s 9D(2)

Patents Act 1977 (UK) ss 125(1), 125(3)

European Patent Convention 2000

Cases cited:

Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; 212 CLR 411

Aldi Foods Pty Ltd v Moroccanoil Israel Ltd [2018] FCAFC 93; 133 IPR 375

Apotex Pty Ltd v Sanofi-Aventis [2008] FCA 1194; 78 IPR 485

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50; 253 CLR 284

Apotex Pty Ltd v Warner-Lambert Company LLC (No 2) [2016] FCA 1238; 122 IPR 17

AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; 226 FCR 324

Branir Pty Ltd v Owston Nominees (No 2) Pty Ltd [2001] FCA 1833; 117 FCR 424

Bristol-Myers Squibb Company v FH Faulding & Company Limited [2000]FCA 316; 97 FCR 524

Bristol-Myers Squibb Co v FH Faulding & Co Ltd (1998) 41 IPR 467

Flour Oxidizing Company Ltd v Carr & Company Ltd (1908) 25 RPC 428

General Tire & Rubber Co Ltd v Firestone Tyre & Rubber Co Ltd [1972] RPC 457

Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2014] FCAFC 73; 222 FCR 336

Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2018] FCAFC 183; 267 FCR 428

Generics (UK) v Warner-Lambert Company LLC [2018] UKSC 56; [2018] RPC 21

Hill v Evans (1862) 31 LJ Ch 456; 4 De GF & J 288; 45 ER 1195

Hospira UK Ltd v Genentech Inc [2014] EWHC 1094 (Pat)

Hospira UK Limited v Genentech Inc [2015] EWHC 1796 (Pat); [2016] RPC 1

ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc [2000] FCA 1349; 106 FCR 214

InterPharma Pty Ltd v Hospira,…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCAFC 116
Decision Date

CaseChat Overview and Summary

Mylan Health Pty Ltd sought to appeal against a decision finding that claims 12 and 13 of its patent were invalid, while Sun Pharma ANZ Pty Ltd sought to contend against the appeal. The dispute centred on issues of patent infringement, validity, and the correct approach to determining infringement and validity. The Federal Court of Australia was the forum for this dispute.

The legal issues addressed by the court included whether Swiss type claims in a patent required an intention to be proven for infringement, the correct test for determining lack of novelty, the approach to establishing a lack of inventive step, and the proper construction of the patent specification to determine if claims were fairly based on the matter described.

The court found that the primary judge correctly determined that claims 12 and 13 were not fairly based on the matter described in the specification. The court held that the correct approach to determining infringement did not require establishing the manufacturer’s intention, and that the test for lack of novelty should not be based solely on a reasoned hypothesis. Additionally, the court found that the primary judge did not err in finding a lack of inventive step based on common general knowledge and documentary disclosure. As a result, Mylan’s appeal and Sun Pharma’s notice of contention were dismissed, and Mylan was ordered to pay Sun Pharma’s costs.

The orders of the court were that Mylan’s appeal be dismissed, Sun Pharma’s notice of contention be dismissed, and Mylan pay Sun Pharma’s costs. These orders reflect the court’s findings on the validity and infringement of the patent claims in question.

Orders

Orders of the court

1. The appeal be dismissed.

2. The first respondent’s notice of contention be dismissed.

3. The appellants pay the first respondent’s costs.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

For these reasons, the primary judge was correct to conclude that claims 12 and 13 of the 964 patent are not fairly based on matter described in the specification. Grounds 22 to 25 of the amended notice of appeal must be dismissed. Conclusion and disposition For these reasons, Mylan’s appeal and Sun Pharma’s notice of contention should be dismissed. Mylan should pay Sun Pharma’s costs.

Ratio Decidendi

Legal Principle Established